Capmatinib Use in MET-Amplified Glioblastoma

Glioblastoma is the most common malignant brain tumor.They are classified as IDH-wild type and characterized by the World Health Organization as a grade 4 tumor.Patients' median survival is 15 months, and treatment options are limited because of treatment side effect profiles and the difficulty of crossing the blood-brain barrier.The standard of care is surgical resection, radiation, and chemotherapy with temozolomide, a DNA alkylating agent that damages DNA and promotes tumor cell death.We present a case of a patient diagnosed with glioblastoma with MET amplification identified via genomic sequencing (copy number, 138) who experienced a clinical and radiographic response to capmatinib.The patient initially received the standard-of-care treatment but experienced disease progression a year and a half after his diagnosis.He then trialed lomustine, another alkylating agent, but imaging continued to show disease progression.He was then prescribed capmatinib, a MET inhibitor that crosses the blood-brain barrier and is primarily used to treat non-small cell lung cancer, combined with bevacizumab, a VEGF monoclonal antibody.The patient tolerated this treatment for an additional year and a half before experiencing disease progression.Capmatinib combined with bevacizumab showed success for this patient and may increase progression-free survival for patients with METamplified glioblastoma.